Effect of bupropion on nocturnal urinary free cortisol and its association with antidepressant response

Journal of Psychiatric Research

Volumn 39, Issue 2, 2005, Pages 183-190

  Rao, Uma ^a   Ott, Geoffrey E ^b   Lin, Keh Ming ^c   Gertsik, Lev ^b   Poland, Russell E ^b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Harbor UCLA Res and Educ Institute   (United States)

Author keywords

Antidepressant; Bupropion; Cortisol; Depression; HPA axis; Treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; HYDROCORTISONE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME; URINALYSIS;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; PLACEBOS;

EID: 10044279468     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2004.01.009     Document Type: Article

References (54)

1. Arias B., Catalan R., Gasto C., Gutierrez B., Fananas L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-week follow-up study. Journal of Clinical Psychopharmacology. 23:2003;563-567
2. Banki C.M., Karmacsi L., Bissette G., Nemeroff C.B. CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. European Neuropsychopharmacology. 2:1992;107-113
3. Brady L.S., Whitfield H.J. Jr., Fox R.J., Gold P.W. Long-term antidepressant administration alters corticotropin releasing hormone, tyrosine hydroxylase and mineralocorticoid receptor gene expression in the brain. Therapeutic implications. Journal of Clinical Investigation. 87:1991;831-837
4. Chrousos G.P. Stressors, stress, and neuroendocrine integration of the adaptive response. Annals of New York Academy of Sciences. 851:1998;311-335
5. Cooper B.R., Hester T.J., Maxwell R.A. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine in vivo. Journal of Pharmacology and Experimental Therapeutics. 215:1980;127-134
6. Cooper B.R., Wang C.M., Cox R.F., Norton R., Shea V., Ferris R.M. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology. 11:1994;133-141
7. Dong J., Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology. 155:2001;52-57
8. De Bellis M.D., Gold P.W., Geracioti T.D. Jr., Listwak S.J., Kling M.A. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. American Journal of Psychiatry. 150:1993;656-657
9. De Kloet E.R., Vreugdenhil E., Oitzl M.S., Joels M. Brain corticosteroid receptor balance in health and disease. Endocrine Reviews. 19:1998;269-301
10. Dinan T.G. Novel approaches to the treatment of depression by modulating the hypothalamic-pituitary-adrenal axis. Human Psychopharmacology. 16:2001;89-93
11. Ferris R.M., White H.L., Cooper B.R., Maxwell R.A., Tang F.L.M., Beaman O.J., Russell A. Some neurochemical properties of a new antidepressant, bupropion hydrochloride (Wellbutrin). Drug Development Research. 1:1981;21-35
12. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured clinical interview for DSM-IV axis I disorders: SCID-I clinician version. 1994;American Psychiatric Association, Washington, DC
13. Gertsik L., Poland R.E. Psychoneuroendocrinology. Schatzberg A.F., Nemeroff C.B. Textbook of psychopharmacology. 3rd ed.:2004;115-129 The American Psychiatric Publishing, Washington, DC
14. Gill M., Daly G., Heron S., Hawi Z., Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Molecular Psychiatry. 2:1997;311-313
15. Goodnick P.J., Dominguez R.A., DeVane C.L., Bowden C.L. Bupropion slow-release response in depression: diagnosis and biochemistry. Biological Psychiatry. 44:1998;629-632
16. Hamilton M. A rating scale for depression. Journal of Neurology Neurosurgery and Psychiatry. 25:1960;56-62
17. Heuser I., Bissette G., Dettling M., Scheweiger U., Gotthardt U., Schmider J., Lammers C.-H., Nemeroff C.B., Holsboer F. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depression and Anxiety. 8:1998;71-79
18. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:2000;477-501
19. Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. Journal of Affective Disorders. 62:2001;77-91
20. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocrine Reviews. 17:1996;187-205
21. Inder W.J., Prickett T.C.R., Mulder R.T., Donald R.A., Joyce P.R. Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology. 156:2001;73-78
22. Keck M.E., Holsboer F. Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides. 22:2001;835-844
23. Kellendonk C., Gass P., Kretz O., Schutz G., Tronche F. Corticosteroid receptors in the brain: gene targeting studies. Brain Research Bulletin. 57:2002;73-83
24. Laakmann G., Hinz A., Voderholzer U., Daffner C., Muller O.A., Neuhauser H., Neulinger E., Wittmann M. The influence of psychotropic drugs and releasing hormones on anterior pituitary hormone secretion in healthy subjects and depressed patients. Pharmacopsychiatry. 23:1990;18-26
25. McCracken J.T., Poland R.E. Saliva and serum cortisol dynamics following intravenous dexamethasone in normal volunteers. Life Sciences. 45:1989;1781-1785
26. Little J.T., Ketter T.A., Mathe A.A., Frye M.A., Luckenbaugh D., Post R.M. Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression. Biological Psychiatry. 45:1999;285-289
27. Meyer S.E., Chrousos G.P., Gold P.W. Major depression and the stress system: a life span perspective. Development and Psychopathology. 13:2001;565-580
28. Müller M.B., Landgraf R., Keck M.E. Vasopressin, major depression, and hypothalamic-pituitary-adrenocortical desensitization. Biological Psychiatry. 48:2000;330-333
29. Müller M.B., Preil J., Renner U., Zimmermann S., Kresse A.E., Stalla G.K., Keck M.E., Holsboer F., Wurst W. Expression of CRHR1 and CRHR2 in mouse pituitary and adrenal gland: implications for HPA system regulation. Endocrinology. 142:2001;4150-4153
30. Nelson J.C., Davis J.M. DST studies in psychotic depression: a meta-analysis. American Journal of Psychiatry. 154:1997;1497-1503
31. Ott G.E., Rao U., Nuccio I., Lin K.-M., Poland R.E. Effect of bupropion-sr on REM sleep: relationship to antidepressant response. Psychopharmacology. 165:2002;29-36
32. Plotsky P.M., Owens M.J., Nemeroff C.B. Psychoneuroendocrinoly of depression: hypothalamic-pituitary-adrenal axis. Psychiatric Clinics of North America. 21:1998;293-307
33. Poland R.E., Lutchmansingh P., McGeoy S., Au D., Que M., Acosta S., Edelstein M., McCracken J.T. Prenatal stress prevents the desensitization of the corticosterone response to TFMPP by desmethylimipramine, but not by phenelzine, in adult male offspring. Life Sciences. 57:1995;2163-2170
34. Poland R.E., Rubin R.T. Saliva cortisol levels following dexamethasone administration in endogenously depressed patients. Life Sciences. 30:1982;177-181
35. Preskorn S.H., Othmer S.C. Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants. Pharmacotherapy. 4:1984;20-34
36. Purba J.S., Hoogendijk W.J.G., Hofman M.A., Swaab D.F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Archives of General Psychiatry. 53:1996;137-143
37. Raadsheer F.C., van Heerikhuize J.J., Lucassen P.J., Hoogendijk W.J.G., Tilders F.J.H., Swaab D.F. Corticotropin-releasing hormone levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. American Journal of Psychiatry. 152:1995;1372-1376
38. Rao U., McCracken J.T., Lutchmansingh P., Edwards C., Poland R.E. EEG sleep and urinary free cortisol in adolescent depression: a preliminary report of changes from episode to recovery. Biological Psychiatry. 47:1997;369-373
39. Reul J.M.H.M., Labeur M.S., Grigoriadis D.E., De Souza E.B. Holsboer hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology. 60:1994;509-519
40. Ribeiro S.C., Tandon R., Grunhaus L., Greden J.F. The DST as a predictor of outcome in depression: a meta-analysis. American Journal of Psychiatry. 150:1993;1618-1629
41. Rubin T.R., Poland R.E., Lesser I.M., Winston R.A., Blodgett N. Neuroendocrine aspects of primary endogenous depression I. Cortisol secretory dynamics in patients and matched controls. Archives of General Psychiatry. 44:1987;328-336
42. Schatzberg A.F., Posner J.A., Rothschild A.J. The role of dopamine in psychotic depression. Clinical Neuropharmacology. 18:1995;S66-S73
43. Schatzberg A.F., Rothschild A.J., Langlais P.J., Bird E.D., Cole J.O. A corticosteroid/dopamine hypothesis for psychotic depression and related states. Journal of Psychiatric Research. 19:1985;57-64
44. Schulkin J., Gold P.W., McEwen B.S. Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology. 23:1998;219-243
45. Shapiro S.S., Wilk M.B. An analysis of variance test for normality (complete samples). Biometrika. 52:1965;591-611
46. Stanford S.C. Monoamines in response and adaptation to stress. Stanford S.C., Salmon P. Stress: from synapse to syndrome. 1993;281-331 Academic Press, London
47. Sullivan R.M., Gratton A. Prefrontal cortical regulation of hypothalamic-pituitary-adrenal function in the rat and implications for psychopathology: side matters. Psychoneuroendocrinology. 27:2002;99-114
48. Thase M.E., Simons A.D., Reynolds C.F. Psychobiological correlates of poor response to cognitive behavior therapy: potential indications for antidepressant pharmacotherapy. Psychopharmacology Bulletin. 29:1993;293-301
49. Raap D.K., Van de Kar Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sciences. 65:1999;1217-1235
50. Veith R.C., Lewis N., Langohr J.I., Murburg M.M., Ashleigh E.A., Castillo S., Peskind E.R., Pascualy M., Bisette G., Nemeroff C.B., Raskind M.A. Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Research. 46:1993;1-8
51. Wada K., Yamada N., Sato T., Suzuki H., Miki M., Lee Y., Akiyama K., Kuroda S. Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures. Psychosomatics: Journal of Consultation Liaison Psychiatry. 42:2001;461-466
52. Wisor J.P., Seiji N., Sora I., Uhl G.H., Mignot E., Edgar D.M. Dopaminergic role in stimulant-induced wakefulness. Journal of Neurosciences. 21:2001;1787-1794
53. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., Holsboer F. Effects of the high affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. Journal of Psychiatric Research. 34:2000;171-181
54. Zobel A.W., Yassouridis A., Frieboes R.-M., Holsboer F. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. American Journal of Psychiatry. 156:1999;949-951